Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Stomach Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


11 drugs have received FDA approval for Stomach Cancer . Docetaxel, Doxorubicin Hydrochloride, Fluorouracil, Imatinib Mesylate, Mitomycin, Pembrolizumab, Ramucirumab, Regorafenib, Sunitinib Malate, Trastuzumab and Trifluridine
242 drugs have a clinical trial registered for Stomach Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 1309 clinical trials for Stomach Cancer,
763 of which have one or more drug interventions,
546 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 163 Cell Line Models for Stomach Cancer.

Source: COSMIC
(see details)

Chemistry


There are 2192 Compounds which have been tested in Stomach Cancer , 1391 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Stomach Cancer:
Endometrial Stromal Tumors
Gastrointestinal Stromal Tumors
Sarcoma, Endometrial Stromal
Sex Cord-Gonadal Stromal Tumors
Stomach Neoplasms

The following terms have been mapped from cancer.gov to Stomach Cancer:
Gastric (stomach) and pancreatic adenocarcinoma that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with other types of treatment
Gastric (stomach) cancer
Gastric (stomach) cancer or gastroesophageal junction cancer that is recurrent and either locally advanced or metastatic. It is used in patients whose cancer has the PD-L1 protein and whose disease got worse during or after two or more types of treatment including a fluoropyrimidine and platinum chemotherapy and, in some cases, HER2/neu targeted therapy.????
Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (a type of stomach cancer). It is used in patients whose condition has become worse while taking imatinib mesylate or who are not able to take it
Gastrointestinal stromal tumor that is locally advanced, cannot be removed by surgery, or has metastasized (spread to other parts of the body). It is used in patients whose disease has not gotten better with imatinib mesylate and sunitinib malate
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in adults who have already received at least two treatments with a fluoropyrimidine and platinum chemotherapy and either a taxane or irinotecan and, in some cases, HER2/neu-targeted therapy
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that has metastasized. It is used in patients whose disease is HER2+. This use is approved for the Herceptin and Ogivri brands of trastuzumab
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease has gotten worse after treatment with a fluoropyrimidine or platinum chemotherapy. It is used alone or with paclitaxel
Stomach adenocarcinoma or gastroesophageal junction adenocarcinoma (a rare type of esophageal cancer) that is advanced. It is used in patients whose disease has not been treated with chemotherapy